SLE patients with renal damage incur higher health care costs

Rheumatology

Volumn 47, Issue 3, 2008, Pages 329-333

  Clarke, Ann E ^a,b   Panopalis, P ^c   Petri, M ^d   Manzi, S ^e,f   Isenberg, D A ^g   Gordon, C ^h   Senecal J L ⁱ   Joseph, L ^a,b   St Pierre, Y ^b   Li, T ^j  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h UNIVERSITY OF BIRMINGHAM   (United Kingdom)

ⁱ UNIVERSITÉ DE MONTRÉAL   (Canada)

^j BRISTOL MYERS SQUIBB   (United States)

more..

Author keywords

Direct costs; Indirect costs; Quality of life; Renal damage; SLE

Indexed keywords

ABSENTEEISM; ADULT; ARTICLE; CANADA; CONFIDENCE INTERVAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DISEASE ASSOCIATION; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH STATUS; HEALTH SURVEY; HUMAN; KIDNEY FAILURE; KIDNEY INJURY; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY OF LIFE; REGRESSION ANALYSIS; SCORING SYSTEM; SHORT FORM 36; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; BAYES THEOREM; CANADA; COHORT STUDIES; COMBINED MODALITY THERAPY; COST OF ILLNESS; COST-BENEFIT ANALYSIS; FEMALE; GREAT BRITAIN; HEALTH CARE COSTS; HUMANS; KIDNEY FUNCTION TESTS; LINEAR MODELS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; QUALITY OF LIFE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 39449137831     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem373     Document Type: Article

References (24)

1. Clarke AE, Petri M, Manzi S et al. The SLE Tri-Nation Study: absence of a link between health resource use and heath outcome. Rheumatology 2004;43:1016-24.
2. Panopalis P, Petri M, Manzi S et al. The Systemic Lupus Erythematosus Tri-nation Study: Cumulative indirect costs. Arthritis Rheum 2007;57:64-70.
3. Huscher D, Merkesdal S, Thiele K, Zeidler H, Schneider M, Zink A. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis 2006;65:1175-83.
4. Nichol MB, Shi S, Knight TK, Wallace DJ, Weisman MH. Eligibility, utilization, and costs in a California Medicaid lupus population. Arthritis Rheum 2004;51:996-1003.
5. Thumboo J, Strand V. Health-related quality of life in patients with systemic lupus erythematosus: An update. Ann Acad Med Singapore 2007;36:115-22.
6. McElhone K, Abbott J, Teh LS. A review of health related quality of life in systemic lupus erythematosus. Lupus 2006;15:633-43.
7. McInnes PM, Schuttinga J, Sansions WR, Stark SP, Klippel JH. The economic impact of treatment of severe lupus nephritis with prednisone and intravenous cyclophosphamide. Arthritis Rheum 1994;37:1000-6.
8. Tse KC, Tang CS, Lio WI, Lam MF, Chan TM. Quality of life comparison between corticosteroid- and-mycofenolate mofetil and corticosteroid- and-oral cyclophosphamide in the treatment of severe lupus nephritis. Lupus 2006;15:371-9.
9. Vu TV, Escalante A. A cornparism of the quality of life of patients with systemic lupus erythematosus with and without end stage renal disease. J Rheumatol 1999;26:2595-601.
10. Hochberg MC. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
11. Panopelis P, Peth M, Manzi S et al. The Systemic Lupus Erythematosus Tri-nation Study: Longitudinal changes in physical and mental well-being. Rheumatology 2005;44:751-5.
12. Fries JF, Spitz PW, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:127-34.
13. Ware JE Jr, Sherbourne CD. The MOS 36 item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
14. The EuroQol Group. EuroQol: A new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
15. Cohen AS, Mermelstain R, Kamarck T et al. Measuring the functional components of social support. In: Sarason IG, Sarason BR, eds. Social support: Theory, research, and applications. The Hague: Martinus Nijhoff 1985;73-94.
16. Ware JE Jr, Snyder MK, Wright R, Davies AR. Defining and measuring patient satisfaction with medical cara. Eval Program Plann 1983;6:247-63.
17. Bombardier C, Gladman DD, Urowttz MB, Caron D, Chang C. The Committee on prognosis studies in SLE. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
18. Gladman DD, Ginzler EM, Goldsmith CH et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for Systemic Lupus Erythematosus. Arthritis Rheum 1996:39:363-9.
19. Rubin D. Multiple imputation for nonresponse in surveys. New York: Wiley, 1987.
20. Aitchison J, Brown JAC. The lognormal distribution: With special reference to its use in economics. Cambridge: Cambridge University Press, 1957.
21. Greene WH. Systems of regression aquations Ch. 17. Econometric analysis, 2nd edn. New York: Macmillan, 1993.
22. Stamm TA, Bauemfeing B, Coenen M et al. Concepts important to persons with systemic lupus erythematosus and their coverage by standard measures of disease activity and health status. Arthritis Rheum 2007;57:1287-95.
23. Rat AC, Boissier MC. Rheumatoid arthritis: Direct and indirect costs. Joint Bone Spine 2004;71:518-24.
24. Isenberg D, Rahman A. Systemic lupus arythematosus - 2005 annus mirabilis? Nat Clin Pract Rheumatol 2006;2:145-52.